Hooman Noorchashm, the cardiac surgeon who, with his late wife, ran a campaign against power morcellation, is stepping up his family's legal complaint against Karl Storz and Brigham & Women's Hospital.
Cancer Research UK calls its Grand Challenge “the most ambitious cancer research grant in the world.” And it may be just that.
“If you want to see what a cure looks like, you already have,” said Tom Whitehead as his daughter Emily joined him at the lectern at the public hearing of the FDA Oncologic Drugs Advisory Committee July 12.“She's standing right beside me.”
The NCI-MATCH trial has met its goal of screening 6,000 patients, but it will not stop there.
The Bidens are now official players in the realm of oncopolitics.
If the June 22 Senate appropriations hearing is an indication, President Donald Trump will encounter considerable difficulty in accomplishing his stated goal of cutting the NIH budget by 21 percent in fiscal 2018.
President Donald Trump announced his intention to name Norman “Ned” Sharpless to serve as the next NCI director. The appointment was announced late on June 9.
Norman “Ned” Sharpless named NCI director by Trump administration
The graphs make it seem so simple:Doctors learn about a new therapy. They start to prescribe it. A standard of care is born. In a matter of months.
Utilization data compiled by Flatiron Health and made available to The Cancer Letter make it possible to visualize the dramatic uptake of immunotherapy drugs in the academic and community settings.
